EPR Studies of the Structures of Abeta Oligomers

About the Research Project
Program
Award Type
Pilot
Award Amount
$150,000
Active Dates
April 01, 2010 - June 30, 2012
Grant ID
A2010362
Goals
Recent studies suggest that amyloid beta oligomers, or aggregation of only a few amyloid beta molecules, are the primary toxic species in the development of Alzheimer’s disease. In this project, we will study the structures of two amyloid beta oligomers with electron paramagnetic resonance (EPR) spectroscopy. This work will help understand the structural basis of neurotoxicity of amyloid beta oligomers and guide the development of new therapeutic strategies.
Summary
Recent studies suggest that amyloid beta oligomers are the primary toxic species in the development of Alzheimer’s disease. Different amyloid beta oligomers have been identified by different investigators. Because the molecular structures of these oligomers are unknown, it is impossible to know how many unique structures exist in the oligomers and how one type of oligomer differs from another type of oligomer. In this project, we will study the structures of two amyloid beta oligomers with a technique called electron paramagnetic resonance (EPR) spectroscopy. This work will help understand the structural basis of toxicity of amyloid beta oligomers and guide the development of new therapeutic strategies. Our experimental approach involves introducing a probe called spin label into the sequence of amyloid beta. Spin label gives rise to an “EPR spectrum”, from which structural information can be extracted. The distance between two spin labels can also be measured. These distances will serve as constraints for computation of structural models of these oligomers. EPR is a powerful technique for protein structure studies, but its application in Alzheimer’s disease has been limited. We plan to explore the applications of existing EPR methods and develop new strategies to study these amyloid beta oligomers. Success in this project will pave the way for more extensive studies of not only Alzheimer’s disease, but also other similar neurodegenerative diseases.
Related Grants
Alzheimer's Disease Research
Increase of ADAM10 Protein Expression in the Brain as an Alzheimer’s Disease Therapeutic
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Jaehong Suh, PhD
Current Organization
Massachusetts General Hospital
Increase of ADAM10 Protein Expression in the Brain as an Alzheimer’s Disease Therapeutic
Active Dates
July 01, 2024 - June 30, 2027

Principal Investigator
Jaehong Suh, PhD
Current Organization
Massachusetts General Hospital
Alzheimer's Disease Research
Novel Molecules to Tackle Toxic Amyloid-Beta Production in Alzheimer's
Active Dates
July 01, 2023 - June 30, 2026
Principal Investigator
Lucía Chávez-Gutiérrez, PhD
Current Organization
Flanders Institute for Biotechnology (Belgium)
Novel Molecules to Tackle Toxic Amyloid-Beta Production in Alzheimer's
Active Dates
July 01, 2023 - June 30, 2026

Principal Investigator
Lucía Chávez-Gutiérrez, PhD
Current Organization
Flanders Institute for Biotechnology (Belgium)
Alzheimer's Disease Research
Identifying Therapeutic Targets to Prevent Amyloid Accumulation
Active Dates
July 01, 2023 - June 30, 2025
Principal Investigator
Arun Upadhyay, PhD
Current Organization
Northwestern University Feinberg School of Medicine
Identifying Therapeutic Targets to Prevent Amyloid Accumulation
Active Dates
July 01, 2023 - June 30, 2025

Principal Investigator
Arun Upadhyay, PhD
Current Organization
Northwestern University Feinberg School of Medicine